CLINICAL TRIALS PROFILE FOR MIFEPREX
✉ Email this page to a colleague
All Clinical Trials for MIFEPREX
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00352911 ↗ | Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects | Completed | VGX Pharmaceuticals, LLC | Phase 2 | 2006-07-01 | The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1 activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at each dose level. |
NCT01224509 ↗ | The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors | Terminated | University of Southern California | N/A | 2004-09-01 | The purpose of this study is to determine the effect of mifepristone on the expression of three cervical EP3 receptor isoforms (EP3-2, EP3-3 and EP3-6) in pregnant women ≤63 days gestational age. |
NCT01333098 ↗ | Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders | Completed | Eric Lenze | Phase 1/Phase 2 | 2012-09-01 | This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and disabling in older adults. One particularly impairing aspect of late-life anxiety disorders is cognitive impairment: impairments in memory and executive function cause disability, impede treatment response to psychotherapy, may lead to dementia, and are not corrected by standard anti-anxiety treatments. This pilot study will test the glucocorticoid antagonist, mifepristone, for cognitive impairment in late-life anxiety disorders. Mifepristone blocks the effects of elevated cortisol levels on glucocorticoid receptors in the brain; it has been studied preliminarily in various neuropsychiatric disorders, such as psychotic depression and bipolar disorder, with well-documented safety and tolerability. |
NCT01333098 ↗ | Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders | Completed | Washington University School of Medicine | Phase 1/Phase 2 | 2012-09-01 | This study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive impairment in older adults with anxiety disorders. Anxiety disorders are common, severe, and disabling in older adults. One particularly impairing aspect of late-life anxiety disorders is cognitive impairment: impairments in memory and executive function cause disability, impede treatment response to psychotherapy, may lead to dementia, and are not corrected by standard anti-anxiety treatments. This pilot study will test the glucocorticoid antagonist, mifepristone, for cognitive impairment in late-life anxiety disorders. Mifepristone blocks the effects of elevated cortisol levels on glucocorticoid receptors in the brain; it has been studied preliminarily in various neuropsychiatric disorders, such as psychotic depression and bipolar disorder, with well-documented safety and tolerability. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MIFEPREX
Condition Name
Clinical Trial Locations for MIFEPREX
Trials by Country
Clinical Trial Progress for MIFEPREX
Clinical Trial Phase
Clinical Trial Sponsors for MIFEPREX
Sponsor Name